Transferred from: Medicilon

On November 19, NVIDIA announced the open-source AI pharmaceutical framework BioNeMo, which is being adopted by more than 200 pharmaceutical companies.

On November 11, Google announced that it had open-sourced the source code and model weights of the latest version of its AI protein structure prediction tool, AlphaFold3, for academic use.

The open source of these two tools marks a new stage for AI pharmaceuticals and heralds the arrival of a new era for global AI pharmaceuticals.

AI + Pharmaceutical

NVIDIA BioNeMo+ Google AlphaFold3, opening the era of AI pharmaceuticals

The open source of Nvidia BioNeMo and Google AlphaFold3 has undoubtedly pushed AI pharmaceuticals to a new peak. As a set of AI toolsets specifically for biomolecular research, the BioNeMo framework can help researchers greatly increase the scale of AI models, analyze massive data sets more efficiently, significantly accelerate the process of new drug design and development, and expand the scale of digital biology research in the global biopharmaceutical and scientific industries. Google's DeepMind's AlphaFold3 AI model predicts protein structures with unprecedented accuracy, providing researchers around the world with more powerful tools and promoting the in-depth development of scientific research.

from the AlphaFold website

This series of initiatives and progress heralds the arrival of a new era of global AI pharmaceuticals. More than 200 institutions have chosen to integrate BioNeMo into their drug discovery workflows, and the widespread adoption of AlphaFold3 has further accelerated the development of new drugs. These tools make drug discovery more efficient, precise, and creative. At the same time, it also promotes interdisciplinary cooperation and exchanges, and promotes the innovation and development of the pharmaceutical industry.

According to PrecedenceResearch, the Al pharmaceutical industry was valued at $1.17 billion in 2023 and is expected to exceed $11.8 billion by 2032, growing at a CAGR of 29.3% from 2023 to 2032.

AI + Pharmaceutical

AI Pharma BD transactions are frequent, and the commercial value is highlighted

In fact, the commercial value of AI pharmaceuticals has been fully realized. Cooperation between domestic AI pharmaceutical companies and internationally renowned pharmaceutical companies is not uncommon, and strong alliances have become the norm. On September 30, Genentech, a subsidiary of Roche, reached an agreement with AI pharmaceutical company Reger Pharma to acquire Reger's next-generation CDK inhibitor portfolio for an upfront payment of US$850 million in cash and other potential milestone payments, on October 7, CSPC Pharmaceutical Group licensed the compound YS2302018 discovered by its AI technology to AstraZeneca with an upfront payment of US$100 million, and on October 10, XtalPi signed a licensing agreement with Janssen Biotech for its AI platform for large molecule drug discovery... …

According to Tech Emergence, AI technology can save the pharmaceutical industry up to $26 billion in R&D costs annually. According to the Boston Consulting Group, the success rate of AI-generated drug molecules in phase I clinical trials is as high as 80%-90%, far exceeding the industry average of 50%. These remarkable results have undoubtedly laid a solid foundation for the wide application of AI pharmaceuticals.

With the continuous penetration of AI in the biomedical field, formulating a scientific and reasonable layout strategy has become a core element for pharmaceutical companies to enhance their competitiveness. How to keep up with the latest developments of AI technology and effectively integrate AI technology into the pharmaceutical process will become an important issue for pharmaceutical companies.

　　AI+CRO

Medicilon AI drug discovery service platform + one-stop biomedical preclinical R&D service platform accelerates the preclinical R&D process of AI drugs

In the wave of AI pharmaceuticals, Medicilon, as a one-stop biomedical preclinical comprehensive R&D service platform, is a pioneer and practitioner in the field of AI+CRO, through the integration of efficient computing and data analysis capabilities of artificial intelligence technology, as well as the professional flexibility of CRO services, it has built an AI drug discovery service platform, which can provide researchers with diversified services such as protein structure prediction and simulation, binding site discovery, information extraction and cleaning, and customized project database construction. In addition, the platform also deeply assists key R&D stages such as Target-to-hit, Hit-to-lead, and Lead-to-PCC, providing a full range of technical support for drug R&D and significantly accelerating the process of drug R&D pipelines.

At present, Medicilon has reached strategic cooperation with a number of AI innovative drug R&D companies such as Insilico Medicine, DRage, and Deeppotential Technology, and has achieved a number of R&D results. For example, Medicilon provides a full set of preclinical R&D services including pharmacokinetics and safety evaluation for Insilico Medicine's ISM3412 drugs. Provided API process development and formulation development services for MDR-001 of Derva Medicine, and jointly promoted the rapid clinical approval of the drug.

The global entry into the era of AI pharmaceuticals will not only change the way drugs are developed, but also bring new growth points and business opportunities to the entire industry, and reshape the future of the biopharmaceutical industry. In the face of this opportunity and challenge, Medicilon will continue to adhere to the service concept of "innovation-driven, quality-oriented", continue to iterate and innovate the R&D technology service platform, and work with global partners to jointly promote the R&D process of AI drugs!

Medicilon (stock code: 688202.HK) Founded in 2004 and headquartered in Shanghai, SH is committed to providing a full range of preclinical new drug research services for global pharmaceutical companies, research institutions and researchers. Medicilon's one-stop comprehensive service helps customers accelerate the process of new drug development with strong project management and more efficient and cost-effective R&D services, covering the whole process of pharmaceutical preclinical new drug research, including drug discovery, pharmaceutical research and preclinical research. By the end of June 2024, Medicilon has provided drug R&D services to more than 2,000 customers around the world, and has participated in the research and development of 490 IND approved clinical trials of new drugs and generic drugs, growing together with high-quality customers at home and abroad. Medicilon will continue to be based on a global vision, focus on China's innovation, and contribute to human health!

(Redirected from: Medicilon).